Cancer Screening Company Stock Soars 17%

Summary of teh News Article: Abbott to Acquire Exact Sciences

Here’s a breakdown⁣ of the key information from the article:

* Acquisition Deal: ‍Abbott Laboratories is buying Exact Sciences Corp. for approximately $21​ billion (or $105 per share).
* Exact ⁣Sciences’‍ Business: Exact Sciences is a cancer screening ⁤test maker, ​most notably known for Cologuard. They are projected to generate around $3 billion⁢ in revenue this year.
* Market Opportunity: The U.S. market for cancer⁣ screening and precision oncology diagnostics is estimated to be worth around $60 billion.
* recent ​Financial Performance: ⁢ Exact Sciences reported $851 million ‌in revenue for the third quarter‌ and forecasts $3.22 – $3.235 billion for the full‌ year.
* Industry Trend: ⁢ Major ⁤pharmaceutical companies are heavily investing in cancer screening and treatment thru internal growth,licensing agreements,and acquisitions.
* Deal Timeline: The acquisition is expected​ to be finalized in the second quarter of next⁤ year.